Amgen is among the global top 10 pharmaceutical companies based on market value. As of September 2017, the company was worth some 138 billion U.S. dollars. Biopharmaceuticals manufactured by Amgen are also among the leading biotech drugs worldwide. Enbrel and Neulasta are the company’s flagship products, responsible for nearly half of Amgen’s total revenue. Interestingly, Amgen generates almost 80 percent of its revenues on the domestic U.S. market.
As is common in the biopharmaceutical industry, Amgen spends a significant proportion of its income on research and development. In 2017, Amgen spent some 16 percent of its revenue on R&D purposes. Some 25 percent of 3.56 billion dollars of R&D spending was for late-stage clinical programs, while the rest was for discovery research and translational sciences, and for marketed products.